Outcomes of Bispecific Antibody Treatment of Double Hit Lymphoma, a Real-World Evidence (RWE) Study
Geoffrey Shouse(City Of Hope National Medical Center), Gulrayz Ahmed(Medical College of Wisconsin), Alex F. Herrera(City of Hope), Steven M. Bair(University of Colorado Cancer Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Allison M. Bock(Mayo Clinic), Amy Ayers(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Ajay Major(University of Colorado Cancer Center), Chijioke Nze(The University of Texas MD Anderson Cancer Center), Sonia Godbole(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Jomel Meeko Manzano(City Of Hope National Medical Center), Omnia Farahat(The University of Texas MD Anderson Cancer Center), Christine Argao, Gilles Salles, Alexey V. Danilov, Swetha Thiruvengadam, Narendranath Epperla, Matthew A. Lunning, Ayushi Chauhan, Christopher R. Flowers, Lu Chen, Manali Kamdar, Andrew Jallouk(Vanderbilt University Medical Center), Sairah Ahmed, Yazeed Sawalha(Cleveland Clinic)
Cited by 0
Related Papers
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
|Journal of Clinical Oncology|2016|187
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Sequence-Based Discovery of <i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome
|New England Journal of Medicine|2013|151